Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Situ Thrombolysis With tPA in Severe COVID-19
NCT04926428Completed
- Sponsor
- Grupo Mexicano para el Estudio de la Medicina Intensiva
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Open-label, single-arm trial of tissue-plasminogen activator in coronavirus disease 2019 (COVID-19), sponsored by Grupo Mexicano para el Estudio de la Medicina Intensiva. Primary endpoint: Changes in lung perfusion at 1 hour. Started Dec 2020; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04926428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926428.